PHAT Phathom Pharmaceuticals

Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference

Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference

FLORHAM PARK, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that company management will participate in one-on-one meetings at the upcoming 19th Annual Needham Virtual Healthcare Conference from Tuesday, April 14, 2020 through Wednesday, April 15, 2020.

About Phathom

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the company’s website at and follow Phathom on LinkedIn at .

CONTACTS

Joe Hand

1-877-742-8466

Media Contact:

Nick Benedetto

1-877-742-8466

Investor Contact:

Patti Bank

Westwicke Partners

415-513-1284

EN
09/04/2020

Underlying

PHATPhathom Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Phathom Pharmaceuticals

 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listi...

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company’s Board of Directors has approved the grant of inducement awards. On May 1, 2025, the Company’s Board of Directors granted inducement awards to Mr. Bentl...

May 1, 2025 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results a...

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call t...

May 1, 2025 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW ...

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting New data includes real-world analyses of VOQUEZNA-treated patients in the U.S. diagnosed with gastroesophageal reflux disease (GERD) FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present real-world data for its first-in-class treatment VOQUEZNA® (vonoprazan) at Digestive Disease Week® (D...

April 28, 2025 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results...

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 • Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a business update. ...

April 23, 2025 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directo...

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and su...

April 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch